Clinical and biological relevance of CREB3L1 in Philadelphia chromosome-negative myeloproliferative neoplasms

被引:1
|
作者
De Marchi, Federico [1 ]
Okuda, Maho [2 ,3 ]
Morishita, Soji [2 ,4 ]
Imai, Misa [2 ]
Baba, Terumi [1 ]
Horino, Mei [1 ]
Mori, Yosuke [1 ]
Furuya, Chiho [1 ]
Ogata, Satoko [4 ]
Yang, Yinjie [4 ]
Ando, Jun [1 ,5 ]
Ando, Miki [1 ]
Araki, Marito [2 ,4 ]
Komatsu, Norio [1 ,2 ,4 ,6 ,7 ]
机构
[1] Juntendo Univ, Dept Hematol, Grad Sch Med, 2-1-1 Hongo,Bunkyo ku, Tokyo 1138421, Japan
[2] Juntendo Univ, Lab Dev Therapies MPN, Grad Sch Med, 2-1-1 Hongo,Bunkyo ku, Tokyo 1138421, Japan
[3] Juntendo Univ, Inst Environm & Gender Specif Med, Grad Sch Med, 2-1-1 Tomioka, Urayasu, Chiba 2790021, Japan
[4] Juntendo Univ, Dept Adv Hematol, Grad Sch Med, 2-1-1 Hongo,Bunkyo ku, Tokyo 1138421, Japan
[5] Juntendo Univ, Dept Cell Therapy & Transfus Med, Grad Sch Med, 2-1-1 Hongo,Bunkyo ku, Tokyo 1138421, Japan
[6] PharmaEssentia Japan KK, 1-3-13 Moto Akasaka,Minato ku, Tokyo 1070051, Japan
[7] 2-1-1 Hongo,Bunkyo ku, Tokyo 1138421, Japan
关键词
CREB3L1; JAK2; CALR; Philadelphia chromosome-negative myelopro-liferative neoplasms (MPNs); Platelet RNA; Unfolded protein response (UPR); ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; MEGAKARYOCYTIC CELL-LINE; TRANSCRIPTION FACTOR; CANCER; OASIS; ESTABLISHMENT; EXPRESSION; HEALTH; FAMILY;
D O I
10.1016/j.leukres.2022.106883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cyclic AMP-response element-binding protein 3-like 1 (CREB3L1) is a gene involved in the unfolded protein response (UPR). Recently, we demonstrated that CREB3L1 is specifically overexpressed in the platelets of patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). In this study, we aimed to show the clinical and biological relevance of CREB3L1 in these hematological diseases. Overexpression of CREB3L1 was specific to platelets in MPNs and associated with a higher risk of thrombosis and fibrotic transformation in essential thrombocythemia (ET) and polycythemia vera (PV) cases, respectively. Furthermore, we found that UPR genes were downregulated in platelets of patients with ET and PV, which were more pronounced in patients harboring the JAK2 V617F mutation. However, CREB3L1 overexpression does not alter UPR gene expression or cell proliferation in UT-7/TPO/CALRm cells exogenously expressing mutated calreticulin and HEL cells harboring endogenous JAK2 V617F. Furthermore, CREB3L1 overexpression did not modulate sensitivity to endoplasmic reticulum stress in these cell lines. Taken together, our data show 1) a potential role of CREB3L1 expression in platelets as a new marker of high-risk MPNs and 2) an association between CREB3L1 over expression and UPR gene downregulation in these patients' platelets, with CREB3L1 not altering UPR in our in vitro models and possibly further in vivo mechanisms being involved.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms
    Morishita, Soji
    Yasuda, Hajime
    Yamawaki, Saya
    Kawaji, Hideya
    Itoh, Masayoshi
    Edahiro, Yoko
    Imai, Misa
    Kogo, Yasushi
    Tsuneda, Satoshi
    Ohsaka, Akimichi
    Hayashizaki, Yoshihide
    Ito, Masafumi
    Araki, Marito
    Komatsu, Norio
    CANCER SCIENCE, 2021, 112 (02) : 884 - 892
  • [2] Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options
    Gotoh, Akihiko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (05) : 616 - 618
  • [3] Impact of Comorbidities in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Ahmed, Shima A.
    Aly, Mai M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S336 - S336
  • [4] Concurrent lymphoid and Philadelphia chromosome-negative myeloproliferative neoplasms
    Miguel Torregrosa, Jose
    Soler, Gloria
    Cancio, Shirley
    Ferrer-Marin, Francisca
    MEDICINA CLINICA, 2015, 145 (07): : 318 - 319
  • [5] Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options
    Akihiko Gotoh
    International Journal of Hematology, 2022, 115 : 616 - 618
  • [6] Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Cristina, Sergio Ferreira
    Polo, Blanca
    Lacerda, Joao F.
    SEMINARS IN HEMATOLOGY, 2018, 55 (04) : 215 - 222
  • [7] Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
    Shallis, Rory M.
    Zeidan, Amer M.
    Wang, Rong
    Podoltsev, Nikolai A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (02) : 177 - 189
  • [8] Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Vannucchi, Alessandro M.
    Masala, Giovanna
    Antonioli, Elisabetta
    Susini, Maria Chiara
    Guglielmelli, Paola
    Pieri, Lisa
    Maggi, Laura
    Caini, Saverio
    Palli, Domenico
    Bogani, Costanza
    Ponziani, Vanessa
    Pancrazzi, Alessandro
    Annunziato, Francesco
    Bosi, Alberto
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (07) : 2068 - 2073
  • [9] Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
    Pozdnyakova, Olga
    Hasserjian, Robert P.
    Verstovsek, Srdan
    Orazi, Attilio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (05): : 253 - 261
  • [10] Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
    Holmstrom, Morten Orebo
    Hasselbalch, Hans Carl
    Andersen, Mads Hald
    CANCERS, 2020, 12 (07) : 1 - 21